Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (1667)	9/19/2001 5:15:25 PM
From: Boplicity	Respond to of 2515

hmmm the stock is at 56, BMY is paying billions at 70 a share! hmmm I bought this stock off the chart two weeks ago, very nice cub and handle break out today. b

To: RCMac who wrote (1667)	9/19/2001 7:27:42 PM
From: Miljenko Zuanic	Respond to of 2515

<<Drugmaker Bristol-Myers Squibb Co. (NYSE:BMY - news) said on Wednesday that it would keep 40 percent of the profits from future sales of ImClone Systems Inc.'s (NasdaqNM:IMCL - news) cancer drug IMC2-225 if U.S.>> BMS bigger profit is from chemos, current and what is in pipeline. Generic competition is already here. Their bets (imo) is that C225 will not be sold alone, so they will keep and expand chemo-market. I am not sure will this work. Also, have no idea will IMCL be able to keep competition (anti-EGFr mAb in chemo-combination) at stand-by based on their patents portfolio. Nonetheless, great and superb deal for IMCL and bios. Miljenko